Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

3yrs ago Hedge Fund hedgeco Views: 258

(HedgeCo.Net) The Securities and Exchange Commission has charged Arrayit Corporation, a Sunnyvale, California company, with making false and misleading statements about the development of a COVID-19 test, and with failing to file required financial reports. The SEC also charged Arrayit’s co-founder and Chief Executive Officer, Rene Schena, with making misrepresentations to investors about the financial reports, and for her role as a control person of the company.

The SEC’s complaint alleges that, in March and April 2020, Arrayit falsely stated to investors that it had developed a COVID-19 blood test. In fact, as alleged, at the time, Arrayit had not yet purchased materials needed to make a test. The complaint further alleges that Arrayit falsely asserted to investors that it had submitted the test for emergency approval and that there was a high demand for the test. Additionally, the complaint alleges that, between October 2018 and March 2019, Arrayit issued a series of false and misleading statements to investors, including in a shareholder letter prepared by Rene Schena, claiming that it was preparing to file delinquent periodic reports and financial statements for the first time since November 2015. As alleged, Schena knew or was reckless in not knowing that these claims were untrue.

The SEC’s complaint, filed in the U.S. District Court for the Northern District of California, charges Arrayit with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and the reporting provisions of Section 13(a) of the Exchange Act and Rules 13a-1 and 13a-13 thereunder. The complaint further charges Rene Schena with aiding and abetting Arrayit’s violations and alleges that she is liable as a control person of Arrayit pursuant to Section 20(a) of the Exchange Act. Without admitting or denying the allegations in the complaint, Arrayit and Rene Schena agreed to settle with the Commission and to be enjoined from future violations of the charged provisions. Rene Schena also agreed to a 3-year officer and director bar and to pay a $50,000 penalty. The settlements are subject to court approval.

The Commission previously filed charges against Mark Schena, the President and Chief Science Officer of Arrayit, for related conduct. That matter is currently pending in the U.S. District Court for the Northern District of California.


Today's Hedge Fund Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.